nach oben

Current Infectious Disease Reports

Erschienen in:

01.08.2014 | Transplant and Oncology (M Ison, Section Editor)

Clostridium difficile Infection (CDI) in Solid Organ and Hematopoietic Stem Cell Transplant Recipients

verfasst von: Carolyn D. Alonso, Mini Kamboj

Erschienen in: Current Infectious Disease Reports | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Patients undergoing solid organ and stem cell transplantation are at increased risk of Clostridium difficile infection (CDI) compared with nontransplant patients. CDI may be associated with significant morbidity in this population including prolonged hospitalization, increased hospital charges, and complications in the transplanted organ. A combination of host factors, including both B-cell and T-cell immunosuppression, in addition to traditional risk factors for CDI such as broad-spectrum antibacterial exposure, are likely to contribute to the elevated risk in this population. This article addresses the current epidemiology and risk factors for CDI in transplant recipients, the downstream complications following this infection, and current management strategies, with an emphasis on novel approaches for primary and recurrent disease including fecal microbiota transplantation.

Centers for Disease Control and Prevention (CDC). Vital signs: preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep. 2012;61(9):157–62.

Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol. 2009;7(7):526–36.PubMedCrossRef

Centers for Disease Control and Prevention (CDC). Emerging infections program - Healthcare-associated infections projects. www.cdc.gov/hai/eip. Accessed 14 May 2014.

Ziring D, Tran R, Edelstein S, et al. Infectious enteritis after intestinal transplantation: incidence, timing, and outcome. Transplantation. 2005;79(6):702–9.PubMedCrossRef

Trifilio SM, Pi J, Mehta J. Changing epidemiology of Clostridium difficile-associated disease during stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(3):405–9.PubMedCrossRef

Alonso CD, Treadway SB, Hanna DB, et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2012;54(8):1053–63.PubMedCentralPubMedCrossRef

Chopra T, Chandrasekar P, Salimnia H, et al. Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. Clin Transplant. 2011;25(1):E82–7.PubMedCrossRef

Boutros M, Al-Shaibi M, Chan G, et al. Clostridium difficile colitis: increasing incidence, risk factors, and outcomes in solid organ transplant recipients. Transplantation. 2012;93(10):1051–7.PubMedCrossRef

Lee JT, Kelly RF, Hertz MI, et al. Clostridium difficile infection increases mortality risk in lung transplant recipients. J Heart Lung Transplant. 2013;32(10):1020–6.PubMedCrossRef

10.

Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353(23):2442–9.PubMedCrossRef

11.

Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171(5):466–72.PubMedCentralPubMedCrossRef

12.

Rosen JB, Schecter MG, Heinle JS, et al. Clostridium difficile colitis in children following lung transplantation. Pediatr Transplant. 2010;14(5):651–6.PubMedCrossRef

13.

Bajaj JS, Ananthakrishnan AN, Hafeezullah M, et al. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective. Am J Gastroenterol. 2010;105(1):106–13.PubMedCrossRef

14.

Stelzmueller I, Goegele H, Biebl M, et al. Clostridium difficile colitis in solid organ transplantation – a single-center experience. Dig Dis Sci. 2007;52(11):3231–6.PubMedCrossRef

15.

Patriarchi F, Rolla M, Maccioni F, et al. Clostridium difficile-related pancolitis in lung-transplanted patients with cystic fibrosis. Clin Transplant. 2011;25(1):E46–51.PubMedCrossRef

16.

Lee M, Shelton AA, Concepcion WL, et al. Fulminant Clostridium difficile colitis in a post-liver transplant patient. Dig Dis Sci. 2010;55(9):2459–62.PubMedCrossRef

17.

Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002;235(3):363–72.PubMedCentralPubMedCrossRef

18.

Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.PubMedCrossRef

19.

US Food and Drug Administration (FDA). Nucleic acid based tests. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm330711.htm#microbial. Accessed 14 May 2014.

20.

Jain T, Croswell C, Banavasi H, et al. Prospective evaluation of toxigenic and non-toxigenic strains of Clostridium difficile colonization and infection among allogenic hematopoietic stem cell transplant recipients, 2010-2012. ID week 2013; 2–6 October 2013; San Francisco, CA.

21.•

Kamboj M, Babady NE, Marsh JW, et al. Estimating risk of C. difficile transmission from PCR positive but cytotoxin negative cases. PLoS One. 2014;9(2):e88262. Using genetic methods, this article addresses the risk of transmission of C. difficile from cytotoxin-negative/PCR-positive stool samples. The authors found that transmission occurs with greater frequency in cytotoxin-positive/PCR-positive samples, but that cytotoxin-negative/PCR-positive samples do contribute to hospital-based transmission risks. PubMedCentralPubMedCrossRef

22.

Kinnebrew MA, Lee YJ, Jenq RR, et al. Early Clostridium difficile infection during allogeneic hematopoietic stem cell transplantation. PLoS One. 2014;9(3):e90158.PubMedCentralPubMedCrossRef

23.

Kamboj M, Son C, Cantu S, et al. Hospital-onset Clostridium difficile infection rates in persons with cancer or hematopoietic stem cell transplant: a C3IC network report. Infect Control Hosp Epidemiol. 2012;33(11):1162–5.PubMedCentralPubMedCrossRef

24.

Fong KS, Fatica C, Hall G, et al. Impact of PCR testing for Clostridium difficile on incident rates and potential on public reporting: is the playing field level? Infect Control Hosp Epidemiol. 2011;32(9):932–3.PubMedCrossRef

25.

Longtin Y, Trottier S, Brochu G, et al. Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program. Clin Infect Dis. 2013;56(1):67–73.PubMedCrossRef

26.

Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect. 2009;15(12):1067–79.PubMedCrossRef

27.

Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478–98. quiz 499.PubMedCrossRef

28.

Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45(3):302–7.PubMedCrossRef

29.

Belmares J, Gerding DN, Parada JP, et al. Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect. 2007;55(6):495–501.PubMedCrossRef

30.

Dubberke ER, Sadhu J, Gatti R, et al. Severity of Clostridium difficile-associated disease (CDAD) in allogeneic stem cell transplant recipients: evaluation of a CDAD severity grading system. Infect Control Hosp Epidemiol. 2007;28(2):208–11.PubMedCrossRef

31.•

Wang MS, Evans CT, Rodriguez T, et al. Clostridium difficile infection and limitations of markers for severity in patients with hematologic malignancy. Infect Control Hosp Epidemiol. 2013;34(2):127–32. This study compared three severity grading methods and found that traditional severity scores for CDI may underestimate severity of illness in immunosuppressed patients. PubMedCrossRef

32.

See I, Mu Y, Cohen J, et al. NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis. 2014;58(10):1394–400.PubMedCrossRef

33.

Walker AS, Eyre DW, Wyllie DH, et al. Characterisation of Clostridium difficile hospital ward-based transmission using extensive epidemiological data and molecular typing. PLoS Med. 2012;9(2):e1001172.PubMedCentralPubMedCrossRef

34.

Eyre DW, Cule ML, Wilson DJ, et al. Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med. 2013;369(13):1195–205.PubMedCrossRef

35.

Curry SR, Muto CA, Schlackman JL, et al. Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in Clostridium difficile transmission. Clin Infect Dis. 2013;57(8):1094–102.PubMedCentralPubMedCrossRef

36.

Dionne LL, Raymond F, Corbeil J, Longtin J, Gervais P, Longtin Y. Correlation between Clostridium difficile bacterial load, commercial real-time PCR cycle thresholds, and results of diagnostic tests based on enzyme immunoassay and cell culture cytotoxicity assay. J Clin Microbiol. 2013;51(11):3624–30.PubMedCentralPubMedCrossRef

37.

Len O, Rodriguez-Pardo D, Gavalda J, et al. Outcome of Clostridium difficile-associated disease in solid organ transplant recipients: a prospective and multicentre cohort study. Transpl Int. 2012;25(12):1275–81.PubMedCrossRef

38.

Pant C, Anderson MP, O'Connor JA, et al. Association of Clostridium difficile infection with outcomes of hospitalized solid organ transplant recipients: results from the 2009 Nationwide Inpatient Sample database. Transpl Infect Dis. 2012;14(5):540–7.PubMedCrossRef

39.

Mitu-Pretorian OM, Forgacs B, Qumruddin A, et al. Outcomes of patients who develop symptomatic Clostridium difficile infection after solid organ transplantation. Transplant Proc. 2010;42(7):2631–3.PubMedCrossRef

40.

Hashimoto M, Sugawara Y, Tamura S, et al. Clostridium difficile-associated diarrhea after living donor liver transplantation. World J Gastroenterol. 2007;13(14):2072–6.PubMed

41.

Ali M, Ananthakrishnan AN, Ahmad S, et al. Clostridium difficile infection in hospitalized liver transplant patients: a nationwide analysis. Liver Transpl. 2012;18(8):972–8.PubMedCentralPubMedCrossRef

42.

Albright JB, Bonatti H, Mendez J, et al. Early and late onset Clostridium difficile-associated colitis following liver transplantation. Transpl Int. 2007;20(10):856–66.PubMedCrossRef

43.

de Marie S. Diseases and drug-related interventions affecting host defence. Eur J Clin Microbiol Infect Dis. 1993;12 Suppl 1:S36–41.PubMedCrossRef

44.

Theunissen C, Knoop C, Nonhoff C, et al. Clostridium difficile colitis in cystic fibrosis patients with and without lung transplantation. Transpl Infect Dis. 2008;10(4):240–4.PubMedCrossRef

45.

Gunderson CC, Gupta MR, Lopez F, et al. Clostridium difficile colitis in lung transplantation. Transpl Infect Dis. 2008;10(4):245–51.PubMedCrossRef

46.

Lee JT, Hertz MI, Dunitz JM, et al. The rise of Clostridium difficile infection in lung transplant recipients in the modern era. Clin Transplant. 2013;27(2):303–10.PubMedCrossRef

47.

Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357(9251):189–93.PubMedCrossRef

48.

Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med. 1994;330(4):257–62.PubMedCrossRef

49.

Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect. 2009;58(6):403–10.PubMedCrossRef

50.

Verheyden C, Bauer S, Haug M, Fraser T, Budev M, Neuner E. Epidemiology and risk factors for Clostridium difficile infection in lung transplant recipients. ID week 2013; 2–6 October 2013; San Francisco, CA.

51.

Munoz P, Giannella M, Alcala L, et al. Clostridium difficile-associated diarrhea in heart transplant recipients: is hypogammaglobulinemia the answer? J Heart Lung Transplant. 2007;26(9):907–14.PubMedCrossRef

52.

Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342(6):390–7.PubMedCrossRef

53.

Yamani MH, Avery RK, Mawhorter SD, et al. Hypogammaglobulinemia following cardiac transplantation: a link between rejection and infection. J Heart Lung Transplant. 2001;20(4):425–30.PubMedCrossRef

54.

Corales R, Chua J, Mawhorter S, et al. Significant post-transplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon? Transpl Infect Dis. 2000;2(3):133–9.PubMedCrossRef

55.

Sarmiento E, Rodriguez-Molina J, Munoz P, et al. Decreased levels of serum immunoglobulins as a risk factor for infection after heart transplantation. Transplant Proc. 2005;37(9):4046–9.PubMedCrossRef

56.

Neofytos D, Kobayashi K, Alonso CD, et al. Epidemiology, risk factors, and outcomes of Clostridium difficile infection in kidney transplant recipients. Transpl Infect Dis. 2013;15(2):134–41.PubMedCentralPubMedCrossRef

57.

Keven K, Basu A, Re L, et al. Clostridium difficile colitis in patients after kidney and pancreas-kidney transplantation. Transpl Infect Dis. 2004;6(1):10–4.PubMedCentralPubMedCrossRef

58.

Shah SA, Tsapepas DS, Kubin CJ, et al. Risk factors associated with Clostridium difficile infection after kidney and pancreas transplantation. Transpl Infect Dis. 2013;15(5):502–9.PubMed

59.

Alonso CD, Marr KA. Clostridium difficile infection among hematopoietic stem cell transplant recipients: beyond colitis. Curr Opin Infect Dis. 2013;26(4):326–31.PubMedCentralPubMed

60.

Leung S, Metzger BS, Currie BP. Incidence of Clostridium difficile infection in patients with acute leukemia and lymphoma after allogeneic hematopoietic stem cell transplantation. Infect Control Hosp Epidemiol. 2010;31(3):313–5.PubMedCrossRef

61.

Alonso CD, Dufresne SF, Hanna DB, et al. Clostridium difficile infection after adult autologous stem cell transplantation: a multicenter study of epidemiology and risk factors. Biol Blood Marrow Transplant. 2013;19(10):1502–8.PubMedCentralPubMedCrossRef

62.

Bilgrami S, Feingold JM, Dorsky D, et al. Incidence and outcome of Clostridium difficile infection following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;23(10):1039–42.PubMedCrossRef

63.

Arango JI, Restrepo A, Schneider DL, et al. Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant. 2006;37(5):517–21.PubMedCrossRef

64.

van Vliet MJ, Harmsen HJ, de Bont ES, Tissing WJ. The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog. 2010;6(5):e1000879.PubMedCentralPubMedCrossRef

65.

Alegre ML, Bartman C, Chong AS. Microbes and allogeneic transplantation. Transplantation. 2014;97(1):5–11.PubMedCrossRef

66.

Britton RA, Young VB. Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol. 2012;20(7):313–9.PubMedCentralPubMedCrossRef

67.

Jenq RR, Ubeda C, Taur Y, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med. 2012;209(5):903–11.PubMedCentralPubMedCrossRef

68.••

Taur Y, Xavier JB, Lipuma L, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012;55(7):905–14. Using pyrosequencing for 16S ribosomal RNA genes, the authors uncovered major changes in the intestinal flora during allo-HSCT. They were able to correlate microbial shifts with subsequent development of bacteremia in that population. PubMedCentralPubMedCrossRef

69.••

Fricke WF, Maddox C, Song Y, Bromberg JS. Human microbiota characterization in the course of renal transplantation. Am J Transplant. 2014;14(2):416–27. Using 16S rRNA gene amplification, specific differences in the pre-transplant microbiota were observed among kidney transplant recipients and were subsequently associated with adverse events after transplantation, including rejection events and infectious complications. PubMedCrossRef

70.

Dubberke ER, Burdette SD, AST Infectious Diseases Community of Practice. Clostridium difficile infections in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:42–9.PubMedCrossRef

71.

Parmar SR, Bhatt V, Yang J, Zhang Q, Schuster M. A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies. J Oncol Pharm Pract. 2014;20(3):172–82.PubMedCrossRef

72.

Nilsson C, Aschan J, Hentschke P, et al. The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;31(6):429–35.PubMedCrossRef

73.

Gulbis AM, Culotta KS, Jones RB, Andersson BS. Busulfan and metronidazole: an often forgotten but significant drug interaction. Ann Pharmacother. 2011;45(7–8):e39.PubMedCrossRef

74.

Clutter DS, Dubrovskaya Y, Merl MY, et al. Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother. 2013;57(9):4501–5.PubMedCentralPubMedCrossRef

75.•

Cornely OA, Miller MA, Fantin B, et al. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol. 2013;31(19):2493–9. This study was one of the first to explore alternative treatment for CDI using fidaxomicin in an immunosuppressed patient population. PubMedCrossRef

76.

ClinicalTrials.gov. Safety and efficacy of fidaxomicin versus placebo for prophylaxis against Clostridium difficile-associated diarrhea in adults undergoing hematopoietic stem cell transplantation (DEFLECT-1). http://clinicaltrials.gov/show/NCT01691248. Accessed 14 May 2014.

77.

Sato K, Amada N, Sato T, et al. Severe elevations of FK506 blood concentration due to diarrhea in renal transplant recipients. Clin Transplant. 2004;18(5):585–90.PubMedCrossRef

78.

Pogue JM, DePestel DD, Kaul DR, et al. Systemic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with severe graft-versus-host disease of the gastrointestinal tract. Transpl Infect Dis. 2009;11(5):467–70.PubMedCrossRef

79.

Neff G, Zacharias V, Kaiser TE, et al. Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: a case series. Liver Transpl. 2010;16(8):960–3.PubMedCrossRef

80.

Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362(3):197–205.PubMedCrossRef

81.••

Friedman-Moraco RJ, Mehta AK, Lyon GM, Kraft CS. Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients. Am J Transplant. 2014;14(2):477–80. This was the first study to address the efficacy and safety of using fecal microbiota transplantation (FMT) in immunosuppressed, solid organ transplant recipients. In this small study, the outcomes after FMT were good, without significant adverse events noted. PubMedCrossRef

82.

Ihunnah C, Kelly C, Hohmann E, et al. Fecal microbiota transplantation (FMT) for treatment of Clostridium difficile infection (CDI) in immunocompromised patients. Proceedings of the American College of Gastroenterology 2013 Annual Scientific Meeting; 11–16 October 2013; San Diego, CA.

83.

Willems L, Porcher R, Lafaurie M, et al. Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Biol Blood Marrow Transplant. 2012;18(8):1295–301.PubMedCrossRef

84.

Vehreschild MJ, Weitershagen D, Biehl LM, et al. Clostridium difficile infection in patients with acute myelogenous leukemia and in patients undergoing allogeneic stem cell transplantation: epidemiology and risk factor analysis. Biol Blood Marrow Transplant. 2014;20(6):823–8.PubMedCrossRef

85.

Dunbar SA, Zhang H, Tang YW. Advanced techniques for detection and identification of microbial agents of gastroenteritis. Clin Lab Med. 2013;33(3):527–52.PubMedCrossRef

86.

Le Guern R, Herwegh S, Grandbastien B, et al. Evaluation of a new molecular test, the BD Max Cdiff, for detection of toxigenic Clostridium difficile in fecal samples. J Clin Microbiol. 2012;50(9):3089–90.PubMedCentralPubMedCrossRef

87.

Carroll KC, Buchan BW, Tan S, et al. Multicenter evaluation of the verigene Clostridium difficile nucleic acid assay. J Clin Microbiol. 2013;51(12):4120–5.PubMedCentralPubMedCrossRef

88.

Buchan BW, Mackey TL, Daly JA, et al. Multicenter clinical evaluation of the portrait toxigenic C. difficile assay for detection of toxigenic Clostridium difficile strains in clinical stool specimens. J Clin Microbiol. 2012;50(12):3932–6.PubMedCentralPubMedCrossRef

89.

Deak E, Miller SA, Humphries RM. Comparison of Illumigene, Simplexa, and AmpliVue Clostridium difficile molecular assays for diagnosis of C. difficile infection. J Clin Microbiol. 2014;52(3):960–3.PubMedCentralPubMedCrossRef

90.

Lalande V, Barrault L, Wadel S, et al. Evaluation of a loop-mediated isothermal amplification assay for diagnosis of Clostridium difficile infections. J Clin Microbiol. 2011;49(7):2714–6.PubMedCentralPubMedCrossRef

91.

Babady NE, Stiles J, Ruggiero P, et al. Evaluation of the Cepheid Xpert Clostridium difficile Epi assay for diagnosis of Clostridium difficile infection and typing of the NAP1 strain at a cancer hospital. J Clin Microbiol. 2010;48(12):4519–24.PubMedCentralPubMedCrossRef

92.

Navidad JF, Griswold DJ, Gradus MS, Bhattacharyya S. Evaluation of luminex xTAG gastrointestinal pathogen analyte-specific reagents for high-throughput, simultaneous detection of bacteria, viruses, and parasites of clinical and public health importance. J Clin Microbiol. 2013;51(9):3018–24.PubMedCentralPubMedCrossRef

Titel: Clostridium difficile Infection (CDI) in Solid Organ and Hematopoietic Stem Cell Transplant Recipients
verfasst von: Carolyn D. Alonso
Mini Kamboj
Publikationsdatum: 01.08.2014
Verlag: Springer US
Erschienen in: Current Infectious Disease Reports / Ausgabe 8/2014
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-014-0414-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2014

The Current State and Future Prospects of Chronic Hepatitis C Virus Infection Treatment

BK Virus and Its Role in Hematopoietic Stem Cell Transplantation: Evolution of a Pathogen

Adenovirus: Current Epidemiology and Emerging Approaches to Prevention and Treatment

Scabies and Bedbugs in Hospital Outbreaks